In COVID-19 clinical update #53, Daniel Griffin reviews underreporting of infections and long term disease in children, a blood test for T cells, results of phase 3 trials for monoclonal antibodies, preliminary findings on an oral antiviral, clinical trial of ivermectin, and recommendations for upcoming gatherings.
Hosts: Daniel Griffin and Vincent Racaniello
Click arrow to play
Download TWiV 730 (27 MB .mp3, 45 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- SARS-CoV-2 seroprevalence in <18 year olds (MMWR) 4:09
- EUA for T cell test (FDA) 9:04
- Lilly mAb phase 3 results (Lilly) 16:14
- VIR-7831 mAb phase 3 results (Globenewswire) 18:17
- Molnupiravir phase 2a results (Merck) 23:02
- Ivermectin not supported for mild COVID-19 (JAMA) 24:33
- Recommendations for fully vaccinated people (CDC) 29:16
- Letters read on TWiV 730 35:34
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to email@example.com
Dr. Griffin, Why do you feel comfortable recommending J&Js single dose vaccine, but uncomfortable delaying the booster shot for other vaccines? Is there a fundamental difference in the immune response to the different vaccine types? The AZ Oxford vaccine is also an adenovirus vector vaccine but a booster shot is recommended for it. J&J are researching a second shot to see if it will improve efficacy. Surely partial suppression of the virus carries similar risks of propagating variants, regardless of which vaccine is used.
Dr Griffin please discuss outcome results with Dr Chesler.
Dr. Griffin, First, Thank you for your dedication to informing the public and your ongoing efforts to save lives. I had a question about the difference in acceptance between the mRNA vaccines and JnJ for example. Is there any reason to think there may be fewer side effects using the older (JNJ) type vaccines vs the newer mRNA ones? Thanks,